Cetuximab in non-small cell lung cancer

Foluso O. Ademuyiwa, Nasser Hanna

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Advanced non-small cell lung carcinoma (NSCLC) remains a challenge to treat due to its high local and systemic recurrence. The overall survival remains poor despite the approval of several new chemotherapeutic agents in the management of advanced NSCLC. Overexpression or mutations in the EGFR have been shown to be associated with a significant percentage of NSCLC. The development of targeted agents, such as cetuximab, against the EGFR is therefore a rational objective. Several preclinical and clinical studies suggest that cetuximab is active against NSCLC. This paper reviews the application of cetuximab in NSCLC.

Original languageEnglish (US)
Pages (from-to)107-113
Number of pages7
JournalExpert Opinion on Biological Therapy
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2008

    Fingerprint

Keywords

  • Cetuximab
  • Chemotherapy
  • EGFR antibody
  • Epidermal growth factor receptor inhibitor
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this